These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35913268)

  • 1. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study.
    Baccelli A; Koćwin M; Parazzini EM; Rinaldo RF; Centanni S
    J Asthma; 2023 May; 60(5):1050-1053. PubMed ID: 35913268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tailored approach to refractory severe Mepolizumab-associated headache: a case study.
    Salerni C; Baccelli A; Parazzini EM; Rinaldo R; Centanni S
    J Asthma; 2024 Jun; 61(6):649-652. PubMed ID: 38088891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual biologic therapy in a patient with severe asthma and other allergic disorders.
    Caskey JR; Kaufman D
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34016636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma.
    Dedaj R; Unsel L
    J Asthma; 2019 May; 56(5):473-474. PubMed ID: 29733738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of mepolizumab and omalizumab combination therapy in uncontrolled asthma.
    Sezgin ME; Çolak M; Çağlayan Ö; Yumrukuz Şenel M; Aktepe Sezgin EN; Çoban H; Sarıoğlu N; Gemicioğlu B; Erel F
    J Asthma; 2024 Feb; 61(2):173-175. PubMed ID: 37530447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
    Davison J; Doe S
    Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis.
    Arasi S; Costa S; Magazzù G; Ieni A; Crisafulli G; Caminiti L; Chiera F; Vaccaro M; Del Giudice MM; Pajno GB
    Ital J Pediatr; 2016 Mar; 42():32. PubMed ID: 27000314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targets of omalizumab in asthma.
    Sattler C; Garcia G; Humbert M
    Curr Opin Pulm Med; 2017 Jan; 23(1):56-61. PubMed ID: 27798419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
    Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
    Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.